*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Akeso, Inc.
# 康方生物科技（開曼）有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9926)**

## VOLUNTARY ANNOUNCEMENT
## ON-MARKET SHARE PURCHASE

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Group.

On November 25, 2026, the trustee purchased approximately 100,000 shares of the Company on the market for an aggregate consideration of approximately HK$5.5 million. The board of directors of the Company believes that the share purchase reflects the Company's confidence in its business outlook and future prospects. The share purchase was funded by the Company's existing available cash resources.

By order of the Board
**Akeso, Inc.**
**Dr. XIA Yu**
*Chairwoman and executive Director*

Hong Kong, November 25, 2026

*As at the date of this announcement, the board of directors of the Company comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.*